{"id":"berberine-plus-bezafibrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance (berberine)"},{"rate":null,"effect":"Myalgia or muscle pain (fibrate)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperuricemia (fibrate)"}]},"_chembl":{"chemblId":"CHEMBL3739769","moleculeType":"Small molecule","molecularWeight":"345.83"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Berberine is a plant alkaloid that activates AMP-activated protein kinase (AMPK) and improves insulin sensitivity and lipid profiles. Bezafibrate is a peroxisome proliferator-activated receptor (PPAR) agonist that reduces triglycerides and improves HDL cholesterol. The combination targets multiple metabolic pathways to address dyslipidemia and glucose dysregulation.","oneSentence":"Berberine and bezafibrate work together to improve lipid metabolism and glucose control through alkaloid and fibrate mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:11.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dyslipidemia with metabolic dysfunction"},{"name":"Type 2 diabetes with lipid abnormalities"}]},"trialDetails":[{"nctId":"NCT02548832","phase":"PHASE3","title":"Bezafibrate Plus Berberine in Mixed Dyslipidemia","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2013-04","conditions":"Mixed Dyslipidemia","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Berberine, bezafibrate"],"phase":"phase_3","status":"active","brandName":"Berberine plus Bezafibrate","genericName":"Berberine plus Bezafibrate","companyName":"University of Guadalajara","companyId":"university-of-guadalajara","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Berberine plus Bezafibrate has been studied in a clinical trial for the treatment of mixed dyslipidemia. Berberine and Bezafibrate both act as small molecule agonists of the peroxisome proliferator-activated receptor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}